Skip to main content
Fig. 2 | Cardio-Oncology

Fig. 2

From: Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Fig. 2

Incidence of cardiovascular toxicity by type in antineoplastic-naïve patients during pazopanib treatment. Twenty-four of 35 (69%) patients developed some form of CV toxicity with pazopanib treatment. After excluding HTN, 12/35 (34%) patients still developed a CV adverse event. Refer to Table 6 for clinical details of the 4 CV adverse events requiring hospitalization. CV: cardiovascular; HTN: hypertension; QTc: corrected QT interval

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us